A study to assess the effectiveness and safety of afimkibart in people with moderately to severely active ulcerative colitis
A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis
-
Autoimmune Disorder -
Inflammatory Bowel Disease (IBD) -
Ulcerative Colitis
Basic Details
1. Why is this study needed?
Ulcerative colitis (UC) is a health condition that causes inflammation in the inside layer of some parts of the bowel. It often affects the rectum which is the final section of the large intestine and the lower colon - a part of the large intestine. It can cause bleeding sores or a slippery, gel-like substance called mucus to form. This leads to frequent loose stools or bowel movements and bleeding from the rectum. UC can range from mild to severe and may affect daily life. When people with UC have symptoms, it means their UC is ‘active’. Some existing treatments don’t work for everyone, and others may lose their effectiveness over time. This highlights the ongoing need for more effective treatment options.
This study is testing a medicine called afimkibart. It is being developed to treat moderately to severely active UC.
Afimkibart is an experimental medicine. This means health authorities (like the U.S. Food and Drug Administration and European Medicines Agency) have not approved afimkibart for the treatment of UC. This study aims to compare the effects of afimkibart against non-active medicine (placebo) in people with moderately to severely active UC. This will help researchers understand how afimkibart works when treatment is started and continued as injections under the skin.
2. Who can take part in the study?
People aged 18 to 80 years, as well as 16 and 17-year-olds who have reached adult growth in certain countries, can take part in the study if they have moderately to severely active UC and weigh at least 40 kg. They must have active UC confirmed by endoscopy. An endoscopy is a procedure where a doctor uses a flexible tube (called a scope) with a camera on one end to look inside the body. They must also have taken at least 1 other medicine for UC that didn’t work well, stopped working or caused unacceptable unwanted effects.
People may not be able to take part in this study if they have severe UC that requires a hospital stay for treatment, such as surgery. People who have certain other medical conditions such as Crohn’s disease or certain infections also cannot take part. People who are pregnant, planning to become pregnant, or currently breastfeeding cannot take part in the study.
3. How does this study work?
People will be screened to check if they are able to participate in the study. The screening period will take place up to 35 days before the start of treatment.
Everyone who joins this study will be split up into 2 groups randomly (like rolling a dice). They will be given either afimkibart or placebo, as an injection under the skin (subcutaneous injection) every few weeks until Week 24.
This is a ‘placebo-controlled’ study. This means that participants are put in a group that will receive a medicine or a group that will receive ‘placebo’ (a medicine that contains no active ingredients but looks the same and is taken in the same way as the study medicine). Comparing results from the different groups helps researchers know if any changes seen result from the study medicine or occur by chance.
This is a double-blinded study. This means that neither the participants in the study nor the team running it will know which treatment is being given until the study is over. This is done to make sure that the results of the treatment are not affected by what people expected from the received treatment. However, the study doctor can find out which group the participant is in, if the participants' safety is at risk.
After 12 weeks, if the UC has not improved and the study doctor approves, participants can receive open-label afimkibart through week 24. Open-label means everyone involved, including the participant and the study doctor, will know the participant has been given afimkibart.
After completing the 24 week treatment period, if participants agree and the study doctor thinks it’s suitable, they can keep receiving treatment in an optional extension of the study. Everyone who joins the extension will be given afimkibart as an injection under the skin every few weeks. The extension is open-label.
During this study, the study doctor will see participants every few weeks. They will see how well the treatment is working and any unwanted effects participants may have. Participants will have 2 follow-up visits after completing the study treatment, during which the study doctor will check on the participant’s well being. Total time of participation in the study will be up to 10 months (42 weeks) if not joining the optional extension phase. If they choose to join it, the study will last about 2 years. Participants have the right to stop study treatment and leave the study at any time, if they wish to do so.
4. What are the main results measured in this study?
The main result measured in the study to assess if the medicine has worked is the number of participants who have no or very few signs of UC 12 weeks after starting the treatment. Other key results measured in the study include:
- How well afimkibart lowers specific scores for stool frequency and rectal bleeding at 12 weeks
- The number of participants who have no or very few signs of UC from Week 12 all the way through Week 24
- Improvement in the appearance of colon at 12 and 24 weeks (using endoscopy results)
- Improvements in stool urgency, belly pain, tiredness, and overall well-being through Weeks 12 and 24
- The number and seriousness of unwanted effects
5. Are there any risks or benefits in taking part in this study?
Taking part in the study may or may not make participants feel better. But the information collected in the study can help other people with similar health conditions in the future.
It may not be fully known at the time of the study how safe and how well the study treatment works. The study involves some risks to the participant. But these risks are generally not greater than those related to routine medical care or the natural progression of the health condition. People interested in taking part will be informed about the risks and benefits, as well as any additional procedures or tests they may need to undergo. All details of the study will be described in an informed consent document. This includes information about possible effects and other options of treatment.
Risks associated with the study drug
Participants may have unwanted effects of the drug used in this study. These unwanted effects can be mild to severe, even life-threatening, and vary from person to person. During this study, participants will have regular check-ups to see if there are any unwanted effects.
Afimkibart: Participants will be told about the known unwanted effects of afimkibart, and possible unwanted effects based on human and laboratory studies or knowledge of similar medicines. Known unwanted effects include allergic reactions, joint pain, a low number of red blood cells, and wanting to throw up.
Afimkibart and placebo will be given as an injection under the skin. Known unwanted effects of injection include a reaction, swelling or rash on the skin where it has been pricked with a needle to give a treatment.
The study medicine may be harmful to an unborn baby. Women must take precautions to avoid exposing an unborn baby to the study treatment.
This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.
The clinical trial information herein is sourced from public registries such as ClinicalTrials.gov, EuClinicalTrials.eu, and ISRCTN.com. Additional patient-friendly (lay) content has been prepared by Roche to support understanding.
Results Disclaimer
For the latest version of this information please go to www.forpatients.roche.com